AbbVie reports FY 2022 adjusted EPS $13.77 (+16.4% YoY); guides FY 2023 adjusted EPS $10.70-$11.10

AbbVie Inc.

2022-FY EPS reported $6.63 revenue$58,054,000,000

FY 2022 net revenues $58.054B (+3.3% reported, +5.1% operational); Q4 net revenues $15.121B (+1.6% reported, +3.8% operational).
GAAP diluted EPS FY $6.63 (+2.8%); adjusted diluted EPS $13.77 (+16.4%). Q4 GAAP diluted EPS $1.38 (-38.9%); adjusted $3.60 (+16.9%).
Immunology portfolio FY net revenues $28.924B (+14.4%); Humira $21.237B, Skyrizi $5.165B, Rinvoq $2.522B.
Hematologic oncology portfolio FY net revenues $6.577B (-9.0%); Imbruvica $4.568B, Venclexta $2.009B.
2023 adjusted diluted EPS guidance $10.70-$11.10 (excludes IPR&D and milestones); management cites U.S. Humira LOE as headwind.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

AbbVie Inc. reported financial results for the fourth quarter and full year ended December 31, 2022.

Period: the fourth quarter and full year ended December 31, 2022
Result: reported results

Exact text from the filing

On February 9, 2023, AbbVie Inc. issued a press release announcing financial results for the fourth quarter and full year ended December 31, 2022.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

AbbVie Inc. filing history →

Source: SEC EDGAR

accession 0001551152-23-000006

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.